Skip to content

Study on the effect of water-soluble tomato concentrate combined with red yeast on blood lipid levels in subjects with dyslipidemia

Study on the effect of water-soluble tomato concentrate combined with red yeast on blood lipid levels in subjects with dyslipidemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068360
Enrollment
Unknown
Registered
2023-02-16
Start date
2023-02-24
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyslipidemia

Interventions

water-soluble tomato concentrate group:Water-soluble tomato concentrate, oral, 6 months
red yeast group:Red yeast, oral, 6 months
water-soluble tomato concentrate + red yeast group:water-soluble tomato concentrate + red yeast , oral, 6 months
control group:placebo, oral, 6 months

Sponsors

The Second Hospital of Tianjin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Aged 35-50 years, permanent resident in Tianjin; 2. At least 1 compliance with diagnostic criteria for dyslipidemia (2016 Chinese Guidelines for Prevention and Treatment of Adult Dyslipidemia); 3. Have not received the lipomodulation therapy or antiplatelet therapy; 4. Without medical history of serious disease, haemostatic disorders or aspirin tolerance; 5. Voluntarily join the study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those with familial hypercholesterolemia or secondary hyperlipidemia caused by abnormal thyroid function and nephrotic syndrome; 2. Those with diabetes mellitus, coronary heart disease; having abnormal liver and kidney function, rheumatic immune system disease, connective tissue disease, rhabdomyolysis, malignant tumor, and hematological system disease; 3. Those with communication difficulties, cognitive impairment, and mental illness; 4. Pregnant or lactating women; 5. Those with acute and chronic infection, fever, and a history of major surgery and trauma within one month prior to the start of the study; 6. Those taking statins, antiplatelet drugs, and other nutritional supplements within one month prior to the start of the study.

Design outcomes

Primary

MeasureTime frame
lipid profile;

Secondary

MeasureTime frame
platelet activation indicator;safety indicator;blood glucose;anthropometry indicator;cardiometabolic risk indicator;metabolites related indicator;

Countries

China

Contacts

Public ContactMeilin Zhang

Tianjin Medical University

zhangmeilin@tmu.edu.cn+86 138 2176 1583

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026